Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain. van Outersterp I, Tasian SK, Reichert CE, Boeree A, et al. Blood 2024 Feb 23:blood.2023023120. doi: 10.1182/blood.2023023120.

Read + Share

Amedeo Smart

Independent Medical Education

van Outersterp I, Tasian SK, Reichert CE, Boeree A, et al. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain. Blood 2024 Feb 23:blood.2023023120. doi: 10.1182/blood.2023023120.
PMID: 38394665